NCT05574647 (IP7-PACIFIC) is a NA clinical trial of bpMRI in Prostate Cancer, sponsored by Imperial College London.

Who is sponsoring NCT05574647?

NCT05574647 is sponsored by Imperial College London.

What drugs are being tested in NCT05574647?

Interventions in NCT05574647: bpMRI, Image-Fusion targeted and systematic Biopsy.

What condition does NCT05574647 study?

NCT05574647 studies Prostate Cancer, Adenocarcinoma, Prostatic Neoplasms, Prostatic Diseases, Neoplasms.

Is NCT05574647 still recruiting?

NCT05574647 is currently recruiting now. Last updated 24 July 2025.

Last reviewed 2025-07-24 · How we verify

NCT05574647: IP7-PACIFIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer

Recruiting now NA Last updated 24 July 2025

What this trial tests

NA trial testing bpMRI in Prostate Cancer in 3,600 participants. Currently enrolling.

Timeline

2 November 2022

Primary endpoint
31 October 2025

31 January 2026

Quick facts

Lead sponsor	Imperial College London
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	3,600
Start date	2 November 2022
Primary completion	31 October 2025
Estimated completion	31 January 2026
Sites	15 locations across United Kingdom

Drugs / interventions tested

bpMRI
Image-Fusion targeted and systematic Biopsy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →
Adenocarcinoma — all drugs for Adenocarcinoma →
Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Prostatic Diseases — all drugs for Prostatic Diseases →

Sponsor

Imperial College London

Who can join

18 and older, male only, with Prostate Cancer or Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the role of biparametric MRI and image-fusion targeted biopsies for the detection of prostate cancer. To determine whether biparametric MRI (bpMRI) could be recommended as an alternative to multiparametric MRI (mpMRI) for the detection of clinically significant prostate cancers in patients at risk. To determine whether image-fusion targeted biopsy is better than visual-registration (cognitive) targeted biopsy at detecting clinically significant prostate cancers in patients requiring prostate biopsy due to a suspicious MRI.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Contrast-medium administration for prostate MRI: yes! Contrast-medium administration can be abandoned.
Asbach P. · · 2023 · cited 3× · PMID 37420101 · DOI 10.1007/s00330-023-09766-y

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05574647 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 24 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05574647.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing